Drugs / Fish oil concentrate
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05169060 | Jun 2023 → Feb 2027 expected | diabetic neuropathy | University of Iowa | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01780974 | Apr 2013 → Oct 2015 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1/2 | NCT01058941 | Sep 2010 → Dec 2014 | Alzheimer disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1/2 | NCT00122954 | Jul 2005 → Jun 2009 | depressive disorder, multiple sclerosis | Oregon Health and Science University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fish Oil Concentrate | “alpha lipoic acid (racemic) and fish oil concentrate” NCT01780974 ↗ |
| Route | Oral | “Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening)” NCT01058941 ↗ |